CN106361768A - Composition and preparation thereof for adjuvant therapy of hypertension and diabetes - Google Patents
Composition and preparation thereof for adjuvant therapy of hypertension and diabetes Download PDFInfo
- Publication number
- CN106361768A CN106361768A CN201610755215.3A CN201610755215A CN106361768A CN 106361768 A CN106361768 A CN 106361768A CN 201610755215 A CN201610755215 A CN 201610755215A CN 106361768 A CN106361768 A CN 106361768A
- Authority
- CN
- China
- Prior art keywords
- parts
- diabetes
- preparation
- assisting
- compositionss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a composition for adjuvant therapy of hypertension and diabetes. The composition consists of 40-60 parts of potassium chloride, 80-120 parts of lecithin, 240-360 parts of saccharides and 2.4-3.6 parts of magnesium chloride, and the composition can further consist of 24-36 parts of metformin. The invention also provides a preparation which is prepared from the composition, wherein the preparation is in the form of chewing gum, sublingual tablets or hard candies. The composition for the adjuvant therapy of the hypertension and the diabetes provided by the invention can regulate the metabolism of in-vivo potassium ions, so as to treat diabetes complications caused by potassium metabolism imbalance, and simultaneously to keep an in-vivo environment stable; in addition, the composition, which is prepared from a few varieties of raw materials, is low in side effects, and the purpose that various active ingredients supplement each other to develop a synergistic curative effect can be achieved; the preparation, which is prepared into the form of the chewing gum, the sublingual tablets or the hard candies, is more convenient to take and carry, and the preparation, when chewed or kept under a tongue, can stimulate the secretion of saliva, so as to bring benefits for the full absorption of the active ingredients, and in addition, the curative effect of the composition can be fully developed.
Description
Technical field
The invention belongs to field of health care food is and in particular to a kind of compositionss for assisting in treating hypertension, diabetes
And its preparation.
Background technology
Diabetes are one group of metabolic diseases being characterized with hyperglycemia, hyperglycemia be then due to defect of insulin secretion or
Its biological function is impaired, or both have concurrently and cause.Human body defines the metabolism sugar of complete set through the evolution of millions upon millions of years
System, but this set system imperfect, human body sugar metabolic imbalance or a large amount of move after body potassium deficiency easily occurs, now
This set system drawback occurs it is impossible in Fast-Balance body potassium content, it is unbalance now to also result in blood pressure regulating, leads to hypertension
Generation.Diabetes, for a long time with hyperglycemia, lead to various tissues, particularly eye, kidney, heart, blood vessel, the chronic lesion of nerve
And dysfunction, that is, the complication being commonly called as.The mode of the commonly used insulin injection of people adjusts blood glucose, controls sugar for a long time
Urine disease, but this kind of mode does not play significant effect to treatment diabetic complication.Trace it to its cause, the complication of diabetes
It is because the exception of Potassium Metabolism leads to mostly, do not have significant correlation with the content of insulin.For example, enter blood potassium before the meal to be in
Normal condition, now intracellular potassium content is not enough；Enter after the meal, insulin, by sugar and potassium metabolism simultaneously, makes human body enter low potassium shape
State, appearance is powerless, the symptom potassium deficiency such as dyspepsia, arrhythmia can cause hypernatremia, leads to blood pressure to raise；Blood sodium mistake simultaneously
Height can cause cell expansion, cell function impaired, and particularly blood capillary is easier to cause blocking, may lead to glycosuria when serious
Sick oculopathy, the generation of nephropathy；The rising of kidney pressure can lead to uric acid to raise, thus leading to sclerosis of blood vessels and whole body or localised blood pressure liter
Height, causes numbness, the distending pain of limb end.Now except supplementing potassium, supplemented with suitable phosphorus, common by phosphorus and potassium
Effect, reaches the effect of relief of symptoms；At the same time it can also the magnesium appropriate by supplement, adjust vasoconstriction and diastole, remain thin
The normal function of born of the same parents' ion channel, to adjust blood pressure, to prevent the loss of intracellular potassium ion.Authorization Notice No. is
The patent of invention of cn102894249a discloses a kind of physical fatigue relieving nutrient liquid, including potassium chloride, lecithin, sucrose,
Peanut Polypeptide, lact albumin hydrolysate and Multiple components, can quickly supplement the nutrient substance of needed by human body, recover generation with rapid
Thank to balance, maintain homeostasis.Therefore, by supplementing potassium, P elements in good time, and ensure the supply of sugar, to diabetes simultaneously
Send out disease and can also play certain therapeutical effect.
Content of the invention
In order to solve above-mentioned technical problem, the invention provides a kind of combination for auxiliary treatment diabetes, hypertension
Thing and its preparation.
Concrete technical scheme of the present invention is as follows:
One aspect of the present invention provides a kind of compositionss for auxiliary treatment diabetes, hypertension, including following weight
The composition of number: 40～60 parts of potassium chloride, 80～120 parts of lecithin, sugared 240～360 parts and 2.4～3.6 parts of magnesium chloride, institute
State at least one in glucose, Fructose, maltose or sucrose for the sugar.
Further, described compositionss also include the metformin that parts by weight are 24～36 parts.
The compositionss that the present invention provides can supplement potassium, P elements and the sugar of needed by human body, simultaneously to internal potassium ion
Metabolism is adjusted, and to treat the diabetic complication leading to because Potassium Metabolism is unbalance, maintains stablizing of organismic internal environment simultaneously, changes
Kind health status.
In order to easy to use, the invention provides a kind of preparation for assisting in treating hypertension, diabetes, including aforementioned
Compositionss, described preparation is selected from chewing gum, Sublingual tablet, hard sugar, spray or mixture.
One aspect of the present invention provides a kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum bag
Include the composition of following parts by weight: 15～25 parts of described compositionss, 20～35 parts of gum base, 5～10 parts of plasticizer.
Further, described gum base is the mixture of Konjac glucomannan, polyvinyl acetate and gutta-percha, described Konjac glucomannan,
The ratio of weight and number of polyvinyl acetate and gutta-percha is: 1～2:2:1.
Konjac glucomannan, polyvinyl acetate and gutta-percha are used in combination, viscosity and the elasticity of gum base can be obviously improved,
Substantially improve the mouthfeel of chewing-gum chewing.
Further, described plasticizer is the mixture of Apis cerana Fabriciuss, candelilla wax and acetyl group methyl ricinoleate, described honey
The ratio of weight and number of wax, candelilla wax and acetyl group methyl ricinoleate is 1:1:1～2.
Apis cerana Fabriciuss, candelilla wax and acetyl group methyl ricinoleate are used in combination, the plastic of chewing gum can be significantly increased
Property, and the softness of lifting chewing gum and degree of lubrication further, improve quality and the mouthfeel of chewing gum.
Another aspect of the present invention provides a kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet
Component including following parts by weight: 20～30 parts of described compositionss, 50～70 parts of filler and 0.6～1 part of lubricant.
Further, described filler is hydroxyl isomaltulose, the mixing of Sorbitol, alpha-lactose and Microcrystalline Cellulose
Thing, the ratio of weight and number of described hydroxyl isomaltulose, Sorbitol, alpha-lactose and Microcrystalline Cellulose is 1:1:2:2～4.
Hydroxyl isomaltulose, Sorbitol, alpha-lactose and Microcrystalline Cellulose are used in combination, the tensile strength of Sublingual tablet and
Formability is all considerably better than the effect during diluent only using single component.
Further, described lubricant is the mixture of magnesium stearate, Glyceryl Behenate and magnesium laurylsulfate, institute
The ratio of weight and number stating magnesium stearate, Glyceryl Behenate and magnesium laurylsulfate is 1～3:1:1.
Magnesium stearate, Glyceryl Behenate and magnesium laurylsulfate are used in combination, its greasy property significantly improves, energy
It is obviously improved the efficiency of pelletizing press sheet process, improve the hardness of tablet.
Another aspect of the present invention additionally provides a kind of hard sugar for assisting in treating hypertension, diabetes, described hard sugar bag
Include the component of following parts by weight: 20～30 parts of described compositionss, 10～15 parts of Mel, 10～15 parts of steviol glycosides, Herba Menthae 3～
5 parts, 3～5 parts of concentrated lemon juice and 0.01 part of compound microelement, described compound microelement includes picolinic acid chromium, Portugal
Grape saccharic acid zinc, ferric citrate, manganese sulfate, copper sulfate and cobaltous sulfate.
Mel, steviol glycosides can provide sweet taste for hard sugar, and make user reduce the absorption of sugar；Herba Menthae and concentration lemon
Lemon juice can improve hard sugar mouthfeel, reduces sweet sense；Add compound microelement in hard sugar, user can supplement many with this
Plant element, to maintain the normal physiological function of body.
Present invention also offers the described compositionss for assisting in treating hypertension, diabetes are used for auxiliary treatment in preparation
Application in hypertension, the medicine of diabetes
The invention has the beneficial effects as follows: the compositionss provided by the present invention for assisting in treating hypertension, diabetes can be mended
Fill potassium, P elements and the sugar of needed by human body, by adding magnesium ion, the metabolism of internal potassium ion is adjusted, to control simultaneously
Treat the diabetic complication leading to because Potassium Metabolism is unbalance, and stablizing of organismic internal environment can be maintained, adjust blood pressure；Meanwhile, pass through
Treatment diabetic complication, regulation blood pressure, can alleviate the heart malaise symptoms with appearance, reach auxiliary treatment heart disease
Effect, thus improving the health status of patient on the whole；And the raw materials used kind of the present invention is few, therefore side effect
Little, and it is capable of complementing each other, working in coordination with the purpose playing curative effect of each effective ingredient；Make chewing gum or Sublingual tablet or hard sugar
Afterwards, take and carry convenient, by chewing or buccal, can contribute to fully inhaling effective ingredient with exciting salivary secretion
Receive, and the curative effect of compositionss can be given full play to；Sublingual blood capillary is made quickly to absorb effective ingredient by sublingual administration,
And the speed of this absorption and sugared absorption rate, insulin releasing speed consistent it is ensured that safe and effective；Various auxiliary agents
Adding makes described compound traditional Chinese medicine composite property more stable, helps to maintain its therapeutic effect, and is provided that good mouthfeel, clothes
With convenient.
Specific embodiment
Embodiment 1
A kind of assisting in treating hypertension, the compositionss of diabetes, including 40 parts of potassium chloride, 80 parts of lecithin, glucose 120
Part, 120 parts of maltose and 2.4 parts of magnesium chloride.
Embodiment 2
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 100 parts of lecithin, Fructose 150
Part, 150 parts of sucrose and 3 parts of magnesium chloride.
Embodiment 3
A kind of assisting in treating hypertension, the compositionss of diabetes, including 60 parts of potassium chloride, 120 parts of lecithin, glucose
140 parts, 140 parts of Fructose, 100 parts of maltose, 3.6 parts of magnesium chloride and 36 parts of metformin.
Embodiment 4
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 100 parts of lecithin, glucose
150 parts, 150 parts of sucrose, 3 parts of magnesium chloride and 30 parts of metformin.
Embodiment 5
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes compositionss described in embodiment 1
15 parts, 20 parts of gum base and 5 parts of plasticizer, described gum base includes 5 parts of Konjac glucomannan, 10 parts of polyvinyl acetate and gutta-percha 5
Part.
Embodiment 6
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes compositionss described in embodiment 2
25 parts, 35 parts of gum base and 10 parts of plasticizer, described gum base includes 14 parts of Konjac glucomannan, 14 parts of polyvinyl acetate and gutta-percha
7 parts, described plasticizer includes 2.5 parts of Apis cerana Fabriciuss, 2.5 parts of candelilla wax and 5 parts of acetyl group methyl ricinoleate.
Embodiment 7
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes compositionss described in embodiment 3
25 parts, 35 parts of gum base and 10 parts of plasticizer, described plasticizer includes 3.33 parts of Apis cerana Fabriciuss, 3.33 parts of candelilla wax and acetyl group
3.33 parts of methyl ricinoleate.
Embodiment 8
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes compositionss described in embodiment 4
15 parts, 20 parts of gum base and 5 parts of plasticizer, described gum base includes 6 parts of Konjac glucomannan, 6 parts of polyvinyl acetate and gutta-percha 3
Part, described plasticizer includes 1.25 parts of Apis cerana Fabriciuss, 1.25 parts of candelilla wax and 2.5 parts of acetyl group methyl ricinoleate.
Embodiment 9
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes compositionss described in embodiment 1
20 parts, 50 parts of filler and 0.6 part of lubricant, described filler include 8.33 parts of hydroxyl isomaltulose, 8.33 parts of Sorbitol,
16.66 parts of alpha-lactose and 16.66 parts of Microcrystalline Cellulose.
Embodiment 10
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes compositionss described in embodiment 2
30 parts, 70 parts of filler and 1 part of lubricant, described filler include 8.75 parts of hydroxyl isomaltulose, 8.75 parts of Sorbitol, α-
17.5 parts of Lactose and 35 parts of Microcrystalline Cellulose, described lubricant include 0.6 part of magnesium stearate, 0.2 part of Glyceryl Behenate with
And 0.2 part of magnesium laurylsulfate.
Embodiment 11
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes compositionss described in embodiment 3
30 parts, 70 parts of filler and 1 part of lubricant, described lubricant includes 0.33 part of magnesium stearate, 0.33 part of Glyceryl Behenate
And 0.33 part of magnesium laurylsulfate.
Embodiment 12
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes compositionss described in embodiment 4
20 parts, 50 parts of filler and 0.6 part of lubricant, described filler include 6.25 parts of hydroxyl isomaltulose, 6.25 parts of Sorbitol,
12.5 parts of alpha-lactose and 25 parts of Microcrystalline Cellulose, described lubricant includes 0.2 part of magnesium stearate, 0.2 part of Glyceryl Behenate
And 0.2 part of magnesium laurylsulfate.
Embodiment 13
A kind of hard sugar for assisting in treating hypertension, diabetes, described hard sugar includes 20 parts of described compositionss, Mel 10
Part, 10 parts of steviol glycosides, 3 parts of Herba Menthae, 3 parts of concentrated lemon juice and 0.01 part of compound microelement, described compound microelement
Including picolinic acid chromium, zinc gluconate, ferric citrate, manganese sulfate, copper sulfate and cobaltous sulfate.
Embodiment 14
A kind of hard sugar for assisting in treating hypertension, diabetes, 30 parts of compositionss described in described hard sugar, 15 parts of Mel,
15 parts of steviol glycosides, 5 parts of Herba Menthae, 5 parts of concentrated lemon juice and 0.01 part of compound microelement, described compound microelement includes
Picolinic acid chromium, zinc gluconate, ferric citrate, manganese sulfate, copper sulfate and cobaltous sulfate.
Reference examples 1
A kind of assisting in treating hypertension, the compositionss of diabetes, including 100 parts of lecithin, 150 parts of Fructose, 150 parts of sucrose
And 3 parts of magnesium chloride.
Reference examples 2
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 150 parts of glucose, maltose
150 parts and 3 parts of magnesium chloride.
Reference examples 3
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 100 parts of lecithin and chlorination
3 parts of magnesium.
Reference examples 4
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 100 parts of lecithin, glucose
150 parts and 150 parts of Fructose.
Reference examples 5
A kind of assisting in treating hypertension, the compositionss of diabetes, including 100 parts of lecithin, 200 parts of glucose, magnesium chloride 3
Part and 30 parts of metformin.
Reference examples 6
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 300 parts of glucose, magnesium chloride 3
Part and 30 parts of metformin.
Reference examples 7
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 100 parts of lecithin, magnesium chloride 3
Part and 30 parts of metformin.
Reference examples 8
A kind of assisting in treating hypertension, the compositionss of diabetes, including 50 parts of potassium chloride, 100 parts of lecithin, glucose
200 parts and 30 parts of metformin.
Reference examples 9
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes the combination described in reference examples 1
25 parts of thing, 35 parts of gum base and 10 parts of plasticizer, described gum base is polyvinyl acetate, described plasticizer include 5 parts of Apis cerana Fabriciuss with
And 5 parts of acetyl group methyl ricinoleate.
Reference examples 10
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes the combination described in reference examples 2
25 parts of thing, 35 parts of gum base and 10 parts of plasticizer, described gum base includes 14 parts of gutta-percha and 21 parts of polyvinyl acetate, described
Plasticizer is 2.5 parts of Apis cerana Fabriciuss.
Reference examples 11
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes the combination described in reference examples 4
25 parts of thing, 35 parts of gum base and 10 parts of plasticizer, described gum base includes 14 parts of Konjac glucomannan and 21 parts of polyvinyl acetate, described
Plasticizer includes 5 parts of Apis cerana Fabriciuss and 5 parts of acetyl group methyl ricinoleate.
Reference examples 12
A kind of chewing gum for assisting in treating hypertension, diabetes, described chewing gum includes the combination described in reference examples 5
25 parts of thing, 35 parts of gum base and 10 parts of plasticizer, described gum base includes 14 parts of gutta-percha and 21 parts of polyvinyl acetate, described
Plasticizer includes 5 parts of candelilla wax and 5 parts of acetyl group methyl ricinoleate.
Reference examples 13
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes compositionss described in reference examples 1
30 parts, 70 parts of filler and 1 part of lubricant, described filler includes 35 parts of hydroxyl isomaltulose and 35 parts of Sorbitol, institute
State lubricant and include 0.6 part of magnesium stearate and 0.4 part of magnesium laurylsulfate.
Reference examples 14
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes compositionss described in reference examples 2
30 parts, 70 parts of filler and 1 part of lubricant, described filler includes 35 parts of alpha-lactose and 35 parts of Microcrystalline Cellulose, described
Lubricant includes 0.6 part of magnesium stearate and 0.4 part of Glyceryl Behenate.
Reference examples 15
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes combination described in 4 groups of reference examples
30 parts of thing, 70 parts of filler and 1 part of lubricant, described filler includes 20 parts of hydroxyl isomaltulose, 20 parts of alpha-lactose and micro-
30 parts of crystalline cellulose, described lubricant includes 0.5 part of Glyceryl Behenate and 0.5 part of magnesium laurylsulfate.
Reference examples 16
A kind of Sublingual tablet for assisting in treating hypertension, diabetes, described Sublingual tablet includes combination described in 5 groups of reference examples
30 parts of thing, 70 parts of filler and 1 part of lubricant, described filler includes 30 parts of Sorbitol and 40 parts of Microcrystalline Cellulose,
Described lubricant is magnesium stearate.
Experimental example 1
Chewing-gum chewing mouthfeel evaluation test
The chewing gum being provided using in embodiment 5-8 as experimental group 1-4, the chewing gum that provided using in reference examples 9-12 as
Matched group 1-4.Ask ten valuation officers that each group chewing gum is tasted respectively, and the soft or hard degree to each group fresh goose juice and elasticity
Scored, 50 points of each full marks, amount to 100 points, record the chew time of each group chewing gum simultaneously.Each valuation officer is individually carried out
Scoring, is not mutually exchanged, between tasting twice between every other hour, gargle and use supplement oral cavity moisture with water.
Table 1 each group chewing gum Analyses Methods for Sensory Evaluation Results
As shown in Table 1, the mouthfeel score of experimental group 1-4 is all remarkably higher than matched group 1-4, and chew time is also all notable simultaneously
Higher than matched group 1-4, show the chewing gum of the experimental group each group mouthfeel when chewing more preferably, chew time is longer simultaneously can also
Make the absorption rate of effective ingredient in chewing gum higher, preferably play effect.It follows that by Konjac glucomannan+poly-vinegar acid second
Alkene ester+gutta-percha is combined as gum base, then is aided with Apis cerana Fabriciuss+candelilla wax+acetyl group methyl ricinoleate and combines as plasticizer, can
To give the good quality of chewing gum and mouthfeel, and this effect is significant be better than only use one of which or several individually when
Effect.
Experimental example 2
Sublingual tablet dissolution contrast test
Using the Sublingual tablet of embodiment 9～12 offer as experimental example 1～4, made with the Sublingual tablet that reference examples 13～16 provide
For experimental example 1～4, one of Dissolution of Tablet algoscopys according to 2010 editions records of the Pharmacopoeia of the People's Republic of China " turn basket
Method " is measured to the dissolution of each group Sublingual tablet, and concrete assay method is as follows:
Using deionized water as dissolution medium, it is heated to about 41 DEG C, and is stirred continuously more than 5min under vacuum, obtain
To degassing dissolution medium；Measure the deionized water of degassed process respectively, be placed in 8 stripping rotors, every glass of 500ml, treat dissolution
Medium temperature is constant, and after 37 DEG C ± 0.5 DEG C, every group of sample takes 6, respectively put into 6 dryings turn in basket, basket will be turned and fall into
In stripping rotor, note must not having bubble on test sample surface, start dissolution instrument and be adjusted to 100r/min, record every sample complete
The time of full dissolution, and compare the dissolution rate of each group sample.
The complete dissolution time of table 2 each group Sublingual tablet
As shown in Table 2, the dissolution time of experimental group 1-4 is all substantially less than matched group 1-4, shows the dissolution of experimental group each group
Speed is all remarkably higher than matched group each group.Sublingual tablet should dissolve rapidly in Sublingual when using, and medicine is through hypoglossis mucous membrane capillary
Blood vessel absorbs, and is delivered to whole body to reach therapeutic effect by blood." Chinese Pharmacopoeia " 2010 editions regulations, Sublingual tablet is except as otherwise rule
Fixed outer, all should dissolve in 5min.As can be seen here, the Sublingual tablet dissolution time in experimental group 1～4 all meets national standard.
Therefore, the filler of hydroxyl isomaltulose+Sorbitol+alpha-lactose+Microcrystalline Cellulose is applied in combination, and Sublingual tablet can be made to have well
Result of extraction, and this result of extraction be considerably better than only use one of which or several individually when effect.
Experimental example 3
Diabetic complication clinical experiment
1. test case
Choose diabeticss between 30～60 years old for 160 ages, be randomly divided into 8 groups, every group of 20 people, all patients
Middle no trimester of pregnancy or patient's age of sucking.
2. dosage
The compositionss being provided with embodiment 1-4 are experimental group 1-4, and the compositionss being provided with reference examples 5-8 are for comparison
Group 5-8, allows 8 groups of patients take above 8 set products respectively, every 12 hours 1 time, each 1g, simultaneously according to doctor's advice consumption injection pancreas
Island element, every 12 hours 1 time, continuous treatment 60 days.
3. evaluation index
Clinical manifestation: myasthenia of limbs, numbness of hands and feet, albuminuria, eyes are dry and astringent, blurred vision, arrhythmia
Physiological and biochemical index: diabeticss microdose urine protein content > 20mg/l.
Significantly effective: after treatment, state of an illness sign is obviously improved, microdose urine protein is down to normal range (< 18.14mg/l)；
Effective: after treatment, state of an illness sign makes moderate progress, microdose urine protein significantly reduces and maintains compared with steady statue；
Invalid: no substantially to change before and after treatment.
4. data processing
Finishing analysis are carried out to patient clinical data, by t inspection, the therapeutic effect of experimental group and matched group is compared
Relatively.
5. experimental result
Table 3 each group patient's treatment
Experimental group and matched group significant difference (p < 0.05).
6. analysis and conclusion
As shown in Table 3, the effective percentage of experimental group is all not less than 85%, and matched group each group effective percentage is all less than 65%,
Show experimental group evident in efficacy higher than matched group.And show through follow-up follow-up investigation, one after the medication of matched group some patientss
Year in the recurrence signs such as blurred vision, numbness of hands and feet occur, and 1 year after all patient medication of experimental group in all do not occur bad
Reaction or recurrence sign, show that compositionss provided in an embodiment of the present invention have good therapeutic effect to diabetic complication,
And effect persistently, have no toxic side effect, suitably promoted.
Experimental example 4
Hypertension clinical experiment
1. test case
Choose hyperpietic between 30～60 years old for 160 ages, be randomly divided into eight groups, every group of 20 people, all trouble
No trimester of pregnancy or age of sucking patient in person.
2. dosage
The compositionss being provided with embodiment 1-4 are experimental group 1-4, and the compositionss being provided with reference examples 1-4 are for comparison
Group 1-4, allows eight groups of patients take above eight set products respectively, every 12 hours 1 time, and each 1g continuously takes 30 days.
3. evaluation index
Clinical manifestation: dizziness, headache, psychentonia, absent minded, hypomnesis, numb limbs and tense tendons, cardiopalmus, breast
Vexed, weak etc..
Physiological and biochemical index: hyperpietic's systolic pressure >=140mmhg, diastolic pressure >=90mmhg.
Significantly effective: after treatment, state of an illness sign is obviously improved, and pressure value is down to normal range；
Effective: after treatment, state of an illness sign makes moderate progress, pressure value significantly reduces and maintains compared with steady statue；
Invalid: no substantially to change before and after treatment.
4. data processing
Finishing analysis are carried out to patient clinical data, by t inspection, the therapeutic effect of experimental group and matched group is compared
Relatively.
5. experimental result
Table 4 each group patient's treatment
Experimental group and matched group significant difference (p < 0.05).
6. analysis and conclusion
As shown in Table 4, the effective percentage of experimental group is all not less than 90%, and matched group each group effective percentage is all less than 70%,
Show experimental group evident in efficacy higher than matched group.And show through follow-up follow-up investigation, the medication of matched group some patientss is later half
Dizzy, uncomfortable in chest, numb limbs and tense tendons, the blood pressure high recurrence sign of liter occurs in year, and in experimental group all patient medication later six months all
Untoward reaction or recurrence sign do not occur, shows that compositionss provided in an embodiment of the present invention have to hypertension and good control curative effect
Really, for and effect persistently, have no toxic side effect, suitably promoted.
Embodiment described above only have expressed the several embodiments of the present invention, and its description is more concrete and detailed, but simultaneously
Therefore the restriction to the scope of the claims of the present invention can not be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, some deformation can also be made and improve, these broadly fall into the guarantor of the present invention
Shield scope.Therefore, the protection domain of patent of the present invention should be defined by claims.
Claims (10)
1. a kind of for assisting in treating hypertension, diabetes compositionss it is characterised in that described compositionss include following weight
The composition of number: 40～60 parts of potassium chloride, 80～120 parts of lecithin, sugared 240～360 parts and 2.4～3.6 parts of magnesium chloride, institute
State at least one in glucose, Fructose, maltose or sucrose for the sugar.
2. the compositionss being used for as claimed in claim 1 assisting in treating hypertension, diabetes are it is characterised in that described combination
Thing also includes the metformin that parts by weight are 24～36 parts.
3. a kind of preparation for assisting in treating hypertension, diabetes, including the compositionss described in claim 1 or 2, its feature
It is, described preparation is selected from chewing gum, Sublingual tablet, hard sugar, spray or mixture.
4. it is used for assisting in treating hypertension, the preparation of diabetes as claimed in claim 3 it is characterised in that described preparation is
Chewing gum, described chewing gum includes the composition of following parts by weight: 15～25 parts of described compositionss, 20～35 parts of gum base, plasticising
5～10 parts of agent.
5. it is used for assisting in treating hypertension, the preparation of diabetes as claimed in claim 4 it is characterised in that described gum base is
The mixture of Konjac glucomannan, polyvinyl acetate and gutta-percha, the weight of described Konjac glucomannan, polyvinyl acetate and gutta-percha
Portion rate is: 1～2:2:1.
6. the preparation being used for as claimed in claim 4 assisting in treating hypertension, diabetes is it is characterised in that described plasticizer
For the mixture of Apis cerana Fabriciuss, candelilla wax and acetyl group methyl ricinoleate, described Apis cerana Fabriciuss, candelilla wax and acetyl group ricinoleic acid
The ratio of weight and number of methyl ester is 1:1:1～2.
7. it is used for assisting in treating hypertension, the preparation of diabetes as claimed in claim 3 it is characterised in that described preparation is
Sublingual tablet, described Sublingual tablet includes the composition of following parts by weight: 20～30 parts of described compositionss, 50～70 parts of filler and
0.6～1 part of lubricant.
8. the preparation being used for as claimed in claim 7 assisting in treating hypertension, diabetes is it is characterised in that described filler
For the mixture of hydroxyl isomaltulose, Sorbitol, alpha-lactose and Microcrystalline Cellulose, described hydroxyl isomaltulose, Sorbitol, α-
The ratio of weight and number of Lactose and Microcrystalline Cellulose is 1:1:2:2～4；Preferably, described lubricant is magnesium stearate, behenic acid
Glyceride and the mixture of magnesium laurylsulfate, the weight of described magnesium stearate, Glyceryl Behenate and magnesium laurylsulfate
Amount portion rate is 1～3:1:1.
9. it is used for assisting in treating hypertension, the preparation of diabetes as claimed in claim 3 it is characterised in that described preparation is
Hard sugar, described hard sugar includes the component of following parts by weight: 20～30 parts of described compositionss, 10～15 parts of Mel, steviol glycosides
10～15 parts, 3～5 parts of Herba Menthae, 3～5 parts of concentrated lemon juice and 0.01 part of compound microelement, described compound microelement bag
Include picolinic acid chromium, zinc gluconate, ferric citrate, manganese sulfate, copper sulfate and cobaltous sulfate.
10. the compositionss for assisting in treating hypertension, diabetes described in claim 1 or 2 are used for auxiliary treatment in preparation
Application in hypertension, the medicine of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610755215.3A CN106361768A (en) | 2016-08-29 | 2016-08-29 | Composition and preparation thereof for adjuvant therapy of hypertension and diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610755215.3A CN106361768A (en) | 2016-08-29 | 2016-08-29 | Composition and preparation thereof for adjuvant therapy of hypertension and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106361768A true CN106361768A (en) | 2017-02-01 |
Family
ID=57900612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610755215.3A Pending CN106361768A (en) | 2016-08-29 | 2016-08-29 | Composition and preparation thereof for adjuvant therapy of hypertension and diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106361768A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244822A1 (en) * | 2019-06-06 | 2020-12-10 | Unilever Plc | Use of oral care composition |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090110674A1 (en) * | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| WO2009080020A1 (en) * | 2007-12-20 | 2009-07-02 | Fertin Pharma A/S | Chewing gum tablet and method of dosing pharmaceutically active ingredients in such chewing gum tablet |
| CN102046021A (en) * | 2008-05-26 | 2011-05-04 | 费尔廷制药公司 | Film-coated compressed chewing gum |
| CN102481257A (en) * | 2009-04-24 | 2012-05-30 | Omya发展股份公司 | Particulate material for controlled release of active ingredients |
| CN102550773A (en) * | 2012-02-03 | 2012-07-11 | 中国农业大学 | Concentrated whey protein nutrient rod and preparation method thereof |
| CN102894249A (en) * | 2012-09-06 | 2013-01-30 | 广东省农业科学院农业生物技术研究所 | Physical fatigue relieving nutrient liquid and preparation method thereof |
| CN103202824A (en) * | 2013-02-21 | 2013-07-17 | 陕西华昕经贸有限公司 | Application of pinitol to pharmacy and health care product |
-
2016
- 2016-08-29 CN CN201610755215.3A patent/CN106361768A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090110674A1 (en) * | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| WO2009080020A1 (en) * | 2007-12-20 | 2009-07-02 | Fertin Pharma A/S | Chewing gum tablet and method of dosing pharmaceutically active ingredients in such chewing gum tablet |
| CN102046021A (en) * | 2008-05-26 | 2011-05-04 | 费尔廷制药公司 | Film-coated compressed chewing gum |
| CN102481257A (en) * | 2009-04-24 | 2012-05-30 | Omya发展股份公司 | Particulate material for controlled release of active ingredients |
| CN102550773A (en) * | 2012-02-03 | 2012-07-11 | 中国农业大学 | Concentrated whey protein nutrient rod and preparation method thereof |
| CN102894249A (en) * | 2012-09-06 | 2013-01-30 | 广东省农业科学院农业生物技术研究所 | Physical fatigue relieving nutrient liquid and preparation method thereof |
| CN103202824A (en) * | 2013-02-21 | 2013-07-17 | 陕西华昕经贸有限公司 | Application of pinitol to pharmacy and health care product |
Non-Patent Citations (5)
| Title |
|---|
| 吴和平 张玉华主编: "《临床病理生理学》", 31 January 2015, 第四军医大学出版社 * |
| 张揆一 郑秀华编著: "《高血压病个体化治疗与调养》", 28 February 2014, 金盾出版社 * |
| 张明编著: "《做好自己的营养医生》", 31 January 2014, 天津科学技术出版社 * |
| 路建锋等主编: "《休闲食品加工技术》", 31 August 2012, 中国科学技术出版社 * |
| 高彦祥: "《食品添加剂》", 31 August 2013, 中国林业出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244822A1 (en) * | 2019-06-06 | 2020-12-10 | Unilever Plc | Use of oral care composition |
| CN113924076A (en) * | 2019-06-06 | 2022-01-11 | 联合利华知识产权控股有限公司 | Use of oral care compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100750988B1 (en) | Composition having ginsenosides for treating or preventing diabetes | |
| CN101805688B (en) | Mulberry health-care wine and preparation method thereof | |
| CN101669624A (en) | Chinese medicinal assorted Chinese herbal tea with function of improving woman anemia and preparation method thereof | |
| CN109170470A (en) | A kind of solid beverage and preparation method thereof for treating diabetes | |
| CN104106828A (en) | Solid beverage for reducing blood glucose | |
| CN106361768A (en) | Composition and preparation thereof for adjuvant therapy of hypertension and diabetes | |
| JPH05501854A (en) | Methods and compositions for non-invasive dose-effect administration of lipophilic drugs | |
| CN105708934A (en) | Composition capable of stabilizing blood glucose and reducing blood glucose and preparation process thereof | |
| CN100450532C (en) | Chinese medicinal formulation for treating children's hyperkinetic syndrome | |
| CN107233432A (en) | It is a kind of that pharmaceutical composition, preparation of liver function and preparation method thereof are protected with reducing pressure and sugar | |
| CN101559046A (en) | Therapeutic action of micromolecule sugar alcohol composite on nasal disease | |
| CN108633997A (en) | A kind of healthcare goat milk powder and preparation method thereof with anti-fatigue effect | |
| CN104001003A (en) | Oral liquid and sublingual spraying agent for treating diabetes | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| WO2020233459A1 (en) | Composition for improving memory and preparation method therefor | |
| CN101797371B (en) | Drug combination for weight-reducing massage | |
| CN1053369C (en) | Medicine for treating thyreoidism | |
| CN104825555B (en) | A kind of drug for treating Parkinson's disease, preparation method and preparation | |
| CN107213283A (en) | A kind of antifatigue, Yin Yang balancing food and medicament dual-purpose Chinese medicine composition and preparation method thereof | |
| CN101357218B (en) | Externally used medicine for treating diabetes and preparation method thereof | |
| CN1247228C (en) | Method for preparing Qi-benefiting and blood circulation-promoting pill for treating insufficienty of heart-qi coronary heart disease | |
| CN104906389B (en) | Treat the Chinese medicine of diabete peripheral herve pathology | |
| US20100105634A1 (en) | Use of glucosamine as a mental and physical stress recovery enhancer and a performance enhancer | |
| CN110302266A (en) | A kind of hypoglycemic composition and preparation method thereof | |
| UA141902U (en) | METHOD OF CORRECTION OF MAGNESIUM DEFICIENCY IN THE BODY DURING MASSAGE PROCEDURE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
| RJ01 | Rejection of invention patent application after publication |